NeuroVive Soon to Recruit Patients With Primary Mitochondrial Disease to Test its Oral Treatment Candidate

Print Friendly, PDF & Email

NeuroVive Pharmaceutical AB has completed recruitment of healthy subjects for the second part of an ongoing Phase 1a/b study testing its oral treatment candidate KL1333 for primary mitochondrial disease . The company also announced that it will soon begin the third part of this three-part, double blind, randomized, placebo-controlled, […]